Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update


D'Haese J. G. , Friess H., Ceyhan G.

EXPERT OPINION ON THERAPEUTIC TARGETS, vol.16, no.6, pp.613-618, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 16 Issue: 6
  • Publication Date: 2012
  • Doi Number: 10.1517/14728222.2012.682574
  • Title of Journal : EXPERT OPINION ON THERAPEUTIC TARGETS
  • Page Numbers: pp.613-618

Abstract

Introduction: The chemokine fractalkine/CX3CL1 and its highly selective receptor CX3CR1 mediate critical physiological events during inflammatory responses. The fractalkine/CX3CR1 axis has been shown to play a key role in the pathogenesis and the progression of a large number of diseases in which imbalance of the immune response is frequently seen. Since our last review published in early 2010, the fractalkine/CX3CR1 axis has gained vast attention as a potential therapeutic target in the scientific community, which can be clearly seen in the large number of studies that have been published on this issue since then.